IDO1 and melanoma: Still, the phase III clinical trial of IDO1 inhibitor plus anti‐PD‐1 mAb in advanced melanoma failed to improve overall survival, compared with anti‐PD‐1 monotherapy, which implied the requirement for further improving IDO1 inhibition strategies.175